DOBI Medical International Expands Board of
Mahwah, NJ, October 12, 2004
– DOBI Medical International, Inc. (DBMI.OB) today announced the
appointment of Mr. Brian Vodicka to the company’s Board of Directors,
effective immediately. DOBI Medical has developed the ComfortScan™
system, a non-invasive, non-ionizing optical imaging tool designed to
assist physicians in the diagnosis of breast cancer. The ComfortScan
system is currently the subject of a clinical study, which will be the
fifth and final module of the company’s PMA application to the FDA.
About DOBI Medical International, Inc.
DOBI Medical is a development stage medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal vascularization ("angiogenesis") associated with tumors. DOBI Medical International’s first application of the technology is the ComfortScan system, a gentle, non-invasive, and non-ionizing, optical imaging system designed to assist physicians in the detection and management of breast cancer. The ComfortScan system is intended to achieve this by providing new, physiology-based imagery of abnormal vascularization in the breast that are not readily available today. The ComfortScan system is an investigational device and is not commercially available in the United States.
CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS
Statements contained in this press release may contain
information that includes or is based upon certain "forward-looking
statements" relating to our business. These forward-looking statements
represent management's current judgment and assumptions, and can be
identified by the fact that they do not relate strictly to historical or
current facts. Forward-looking statements are frequently accompanied by
the use of such words as "anticipates," "plans," "believes," "expects,"
"projects," "intends," and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties, and other
factors, including without limitation, those relating to our ability to
timely and successfully complete our patient clinical trials; our
ability to timely and successfully complete and submit our premarket
approval application to the FDA; the timely and final approval by the
FDA of our ComfortScan system as a adjunct to mammography, which
approval in the U.S. cannot be assured; our ability to secure the
additional financing adequate to execute our business plan; the success
of product development and research efforts; our ability to timely meet
U.S. and foreign government laws and industry standards; our ability to
meet U.S. and foreign medical device quality regulation standards
required to maintain our CE Mark, ISO, UL and FDA export certifications;
our ability to timely deliver our products into international markets;
the acceptance and use of our ComfortScan system by physicians, imaging
clinics, and patients; our ability to meet the performance milestones
and obtain the funding to close on the second tranche of the private
placement completed in December, 2003; and our ability to obtain third
party reimbursement from U.S. and foreign government and private payers.
For further information:
DOBI Medical International